Mycovia Pharmaceuticals

Durham, United States Founded: 2018 • Age: 8 yrs
Small molecule therapeutics are developed for recurrent vulvovaginal candidiasis treatment.

About Mycovia Pharmaceuticals

Mycovia Pharmaceuticals is a Healthcare company based in Durham (United States) founded in 2018. Small molecule therapeutics are developed for recurrent vulvovaginal candidiasis treatment. Mycovia Pharmaceuticals offers products and services including VIVJOA. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Fungal. Its competitors include Scynexis, Amplyx Pharmaceuticals and Elion Therapeutics; 3 of its 3 listed competitors have raised funding.

Company details

Founded in 2018 and based in Durham, United States, Mycovia Pharmaceuticals operates in the biopharmaceutical sector. Small molecule-based therapeutics are developed by the company to address recurrent vulvovaginal candidiasis in women. The lead candidate, VT-1161, targets fungal cytochrome P450 sterol 14α-demethylase and has advanced through Phase 2b clinical trials. Focus remains on innovative antifungal treatments within this specialized field.

  • Headquarters Durham, United States
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Website mycovia.com
  • Social LinkedIn X
Operational Areas
Key Metrics
  • Latest Funding Round
    $710K (USD), Grant

    Jun 2018

  • Investors

Products & Services of Mycovia Pharmaceuticals

Mycovia Pharmaceuticals offers a comprehensive portfolio of products and services, including VIVJOA.

VIVJOA
Pharmaceutical Product

Capsules used for treating fungal infections in patients.

Funding Insights of Mycovia Pharmaceuticals

  • Total Rounds 1
  • Last Round Grant — $710,000
  • First Round $710,000

    (Jun 2018)

  • Investors Count 1

All 1 funding rounds of Mycovia Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2018$710,000Grant––
Valuation history

1 investors in total: 1 institutional.

Investors in Mycovia Pharmaceuticals

Mycovia Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Public health and human services are overseen by HHS.
1953hhs.gov
Premium access

Investor details for Mycovia Pharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Mycovia Pharmaceuticals

11 people are tracked at Mycovia Pharmaceuticals (9 in leadership, 2 in team).

NameRoleGroup
Rachel Gee
VP, Project Management and Regulatory AffairsLeadership
Stephen Brand
Chief Development OfficerLeadership
Patrick Jordan
CEOLeadership
Kristen Oberg
VP, OperationsLeadership
Thorsten Degenhardt
Chief Operating OfficerLeadership
Susan McGaurn
Senior Director, Medical AffairsLeadership
Janelle Branoff Ms, Pmp, Ca-Am
Director, Program And Alliance ManagementLeadership
Mark Coffin
Senior Director Pharmaceutical DevelopmentLeadership
Stacey Curelop
Director Of Clinical OperationsLeadership
Shawana Taylor M.d.
Senior Medical Science LiaisonTeam
Miranda Sheldon
Finance ManagerTeam
Premium access

Complete people profiles for Mycovia Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Mycovia Pharmaceuticals

2 dated milestones of Mycovia Pharmaceuticals, from founding to its latest funding, stage changes and deals.

  1. Founded Mycovia Pharmaceuticals is founded.
  2. Funding First funding round of $710K.

Competitors of Mycovia Pharmaceuticals

Mycovia Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Scynexis, Amplyx Pharmaceuticals and Elion Therapeutics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
scynexis.com1999Jersey, United States$62.65M50
Developing glucan synthase inhibitors for the treatment of fungal infections.
amplyx.com2006San Diego, United States$144.31M15
Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma.
eliontx.com2024New York, United States$81M
Therapeutics for invasive fungal infections are developed by Elion Therapeutics.
Premium access

Detailed competitors of Mycovia Pharmaceuticals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Infectious Diseases

3 companies that operate in the same segment as Mycovia Pharmaceuticals (Infectious Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Developer of molecular diagnostic testing solutions
1996Sunnyvale, California, United StatesUSD 19.1 MUSD 87.11 M4,647
Therapeutics for drug-resistant bacterial infections are developed.
2013Cambridge, Massachusetts, United StatesUSD 114.7 MUSD 59.62 M32
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Mycovia Pharmaceuticals

Mycovia Pharmaceuticals was founded in 2018.

Mycovia Pharmaceuticals is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.

Founded in 2018 and based in Durham, United States, Mycovia Pharmaceuticals operates in the biopharmaceutical sector. Small molecule-based therapeutics are developed by the company to address recurrent vulvovaginal candidiasis in women. The lead candidate, VT-1161, targets fungal cytochrome P450 sterol 14α-demethylase and has advanced through Phase 2b clinical trials. Focus remains on innovative antifungal treatments within this specialized field.

Mycovia Pharmaceuticals's top competitors include Scynexis, Amplyx Pharmaceuticals and Elion Therapeutics.

Mycovia Pharmaceuticals offers VIVJOA.

Mycovia Pharmaceuticals has 1 investor. Key investors include HHS.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available